BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 20818175)

  • 1. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
    Hector A; Montgomery EA; Karikari C; Canto M; Dunbar KB; Wang JS; Feldmann G; Hong SM; Haffner MC; Meeker AK; Holland SJ; Yu J; Heckrodt TJ; Zhang J; Ding P; Goff D; Singh R; Roa JC; Marimuthu A; Riggins GJ; Eshleman JR; Nelkin BD; Pandey A; Maitra A
    Cancer Biol Ther; 2010 Nov; 10(10):1009-18. PubMed ID: 20818175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.
    Vouri M; An Q; Birt M; Pilkington GJ; Hafizi S
    Oncotarget; 2015 Jun; 6(18):16183-97. PubMed ID: 25980499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AXL Mediates Esophageal Adenocarcinoma Cell Invasion through Regulation of Extracellular Acidification and Lysosome Trafficking.
    Maacha S; Hong J; von Lersner A; Zijlstra A; Belkhiri A
    Neoplasia; 2018 Oct; 20(10):1008-1022. PubMed ID: 30189359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
    Giles KM; Kalinowski FC; Candy PA; Epis MR; Zhang PM; Redfern AD; Stuart LM; Goodall GJ; Leedman PJ
    Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
    Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
    Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma.
    Fleuren ED; Hillebrandt-Roeffen MH; Flucke UE; Te Loo DM; Boerman OC; van der Graaf WT; Versleijen-Jonkers YM
    Oncotarget; 2014 Dec; 5(24):12753-68. PubMed ID: 25528764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
    Holland SJ; Pan A; Franci C; Hu Y; Chang B; Li W; Duan M; Torneros A; Yu J; Heckrodt TJ; Zhang J; Ding P; Apatira A; Chua J; Brandt R; Pine P; Goff D; Singh R; Payan DG; Hitoshi Y
    Cancer Res; 2010 Feb; 70(4):1544-54. PubMed ID: 20145120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher expression of receptor tyrosine kinase Axl, and differential expression of its ligand, Gas6, predict poor survival in lung adenocarcinoma patients.
    Ishikawa M; Sonobe M; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Date H
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(Suppl 3):S467-76. PubMed ID: 23242819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target.
    Koorstra JB; Karikari CA; Feldmann G; Bisht S; Rojas PL; Offerhaus GJ; Alvarez H; Maitra A
    Cancer Biol Ther; 2009 Apr; 8(7):618-26. PubMed ID: 19252414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model.
    Chen TJ; Mydel P; Benedyk-Machaczka M; Kamińska M; Kalucka U; Blø M; Furriol J; Gausdal G; Lorens J; Osman T; Marti HP
    Physiol Rep; 2021 Dec; 9(23):e15140. PubMed ID: 34877810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
    Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
    Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AXL regulates mesothelioma proliferation and invasiveness.
    Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA
    Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.
    Xu F; Li H; Sun Y
    Biochem Biophys Res Commun; 2014 Nov; 454(4):566-71. PubMed ID: 25450694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion.
    Li W; Xiong X; Abdalla A; Alejo S; Zhu L; Lu F; Sun H
    J Biol Chem; 2018 Oct; 293(40):15397-15418. PubMed ID: 30108175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma.
    Song X; Wang H; Logsdon CD; Rashid A; Fleming JB; Abbruzzese JL; Gomez HF; Evans DB; Wang H
    Cancer; 2011 Feb; 117(4):734-43. PubMed ID: 20922806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy.
    Ghosh AK; Secreto C; Boysen J; Sassoon T; Shanafelt TD; Mukhopadhyay D; Kay NE
    Blood; 2011 Feb; 117(6):1928-37. PubMed ID: 21135257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Gas6 augments Axl and facilitates immune restoration in an intracerebral hemorrhage mouse model.
    Tong LS; Shao AW; Ou YB; Guo ZN; Manaenko A; Dixon BJ; Tang J; Lou M; Zhang JH
    J Cereb Blood Flow Metab; 2017 Jun; 37(6):1971-1981. PubMed ID: 27389179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
    Bansal N; Mishra PJ; Stein M; DiPaola RS; Bertino JR
    Oncotarget; 2015 Jun; 6(17):15321-31. PubMed ID: 26036314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.
    Leconet W; Larbouret C; Chardès T; Thomas G; Neiveyans M; Busson M; Jarlier M; Radosevic-Robin N; Pugnière M; Bernex F; Penault-Llorca F; Pasquet JM; Pèlegrin A; Robert B
    Oncogene; 2014 Nov; 33(47):5405-14. PubMed ID: 24240689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
    Kirane A; Ludwig KF; Sorrelle N; Haaland G; Sandal T; Ranaweera R; Toombs JE; Wang M; Dineen SP; Micklem D; Dellinger MT; Lorens JB; Brekken RA
    Cancer Res; 2015 Sep; 75(18):3699-705. PubMed ID: 26206560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.